Literature DB >> 8389723

Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata.

D J White1, E M Johnson, D W Warnock.   

Abstract

CASE REPORT--SUBJECTS--Three cases are described of long-standing vaginal candidosis due to Candida glabrata. These had failed to respond to local and systemic antifungals. In each case the infecting strain appeared resistant to a range of azole drugs in vitro. CLINICAL COURSE--Case one--This patient recovered following prolonged treatment with oral itraconazole in combination with oral and vaginal nystatin. Case two. Yeasts were eradicated from this patient following cyclical treatment with oral dydrogesterone; prolonged vaginal treatment with nystatin may have helped. Case three. This patient did not respond to a prolonged course of oral itraconazole in combination with vaginal and oral nystatin, oral medroxyprogesterone or intravaginal boric acid. Eradication of C glabrata was finally achieved by local application of 1% gentian violet. Shortly after eradication of the C glabrata infection, both Case two and Case three developed infections with other Candida species responsive to azole antifungals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389723      PMCID: PMC1195041          DOI: 10.1136/sti.69.2.112

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  5 in total

1.  Fluconazole resistance in Candida glabrata.

Authors:  D W Warnock; J Burke; N J Cope; E M Johnson; N A von Fraunhofer; E W Williams
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

2.  Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents.

Authors:  V Redondo-Lopez; M Lynch; C Schmitt; R Cook; J D Sobel
Journal:  Obstet Gynecol       Date:  1990-10       Impact factor: 7.661

3.  Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata.

Authors:  D Kerridge; R O Nicholas
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

4.  Genital yeast infections.

Authors:  J D Oriel; B M Partridge; M J Denny; J C Coleman
Journal:  Br Med J       Date:  1972-12-30

5.  Depo-Provera in the treatment of recurrent vulvovaginal candidiasis.

Authors:  G J Dennerstein
Journal:  J Reprod Med       Date:  1986-09       Impact factor: 0.142

  5 in total
  14 in total

1.  What to do with the patient with recurrent vulvovaginal candidiasis.

Authors:  J S Bingham
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy.

Authors:  D Arzeni; M Del Poeta; O Simonetti; A M Offidani; L Lamura; M Balducci; N Cester; A Giacometti; G Scalise
Journal:  Eur J Epidemiol       Date:  1997-06       Impact factor: 8.082

Review 3.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis.

Authors:  J Fortún; A López-San Román; J J Velasco; A Sánchez-Sousa; E de Vicente; J Nuño; C Quereda; R Bárcena; G Monge; A Candela; A Honrubia; A Guerrero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

5.  Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections.

Authors:  D J White; A R Habib; A Vanthuyne; S Langford; M Symonds
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

6.  Screening protocol for Torulopsis (Candida) glabrata.

Authors:  G Land; J Burke; C Shelby; J Rhodes; J Collett; I Bennett; J Johnson
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

Review 7.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

8.  Comparison of four methodologies for rapid and cost-effective identification of Candida glabrata.

Authors:  J P Fenn; E Billetdeaux; H Segal; L Skodack-Jones; P E Padilla; M Bale; K Carroll
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

9.  The effect of gentian violet on virulent properties of Candida albicans.

Authors:  Su Ying; Sun Qing; Li Chunyang
Journal:  Mycopathologia       Date:  2009-11-24       Impact factor: 2.574

10.  Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays.

Authors:  R N Tiballi; L T Zarins; X He; C A Kauffman
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.